Hikal Ltd

Hikal Earnings Call Transcript: Key Takeaways

Q2 revenue ₹434 Cr, EBITDA ₹45 Cr (10.3%), PAT loss ₹6 Cr. H2 recovery claimed without a quantified bridge; FY guidance reiterated despite H1 loss.

Hikal Investor Presentation: Key Takeaways

Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.

Hikal Results Update

Hikal Ltd reported Q2 FY27 revenue of ₹434 Crore and an EBITDA of ₹45 Crore. The company also announced the commencement of commercial production for Personal Care at its Panoli facility.

Value

₹434.0 Cr

Hikal Q2 FY27 Results: Net Loss of ₹6.1 Cr, Loss Narrows

Hikal Ltd reported revenue from operations of ₹434.2 Cr (+36.3% YoY) and a net loss of ₹6.1 Cr for Q2 FY27.

Key figure

Net loss ₹6.1 Cr

Hikal Bags New Order from Europe-based global agrochemical company

Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.

From

Europe-based global agrochemical company (unnamed)

Execution

Multi-year

Hikal Regulatory Approval

Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.

Hikal Other Announcement

Hikal Ltd filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports routine ownership data with no new transaction.

Hikal Board Meeting Date

Hikal's board meets November 3, 2026 to consider September quarter and half-year results. The results are yet to be approved.

Hikal Other Announcement

Hikal Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as required under SEBI Regulation 31(1)(b).

Hikal Management Change

Hikal Limited announced the cessation of Mr. Jai Hiremath as Executive Chairman and the resignation of Mrs. Sugandha Hiremath. Mr. Anish Swadi was appointed as CEO-Animal Health.

Hikal Other Announcement

Hikal Ltd. has been assigned an ESG rating of "Crisil ESG 65" by Crisil ESG Ratings & Analytics Limited, based on their independent assessment of public data.

Hikal Annual General Meeting

Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.

Hikal Production Started

Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.

Hikal Other Announcement

Hikal Ltd has filed its Business Responsibility and Sustainability Report for FY 2025-26, fulfilling regulatory compliance requirements under SEBI (LODR) Regulations, 2015.

Hikal Annual Report

Hikal Limited has submitted its Annual Report for FY 2025-26 and the Notice of its 38th Annual General Meeting to the stock exchanges.

Hikal Annual General Meeting

Hikal Ltd has scheduled its 38th Annual General Meeting for September 23, 2026. The company fixed September 04, 2026, as the record date for final dividend eligibility.

Hikal Management Change

Hikal Limited has appointed Mr. Sameer Hiremath as Chairman and Managing Director for five years. The appointment is effective from October 1, 2026, subject to shareholder approval.

Execution

5 years

Hikal Earnings Call Transcript: Key Takeaways

Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.

Call

Guides 15% growth